- Aequus Pharmaceuticals ( OTCQB:AQSZF ) signed an agreement for Canadian distribution rights to 10 products of Ireland-based Scope Ophthalmics' over-the-counter ophthalmology portfolio.
- The products include the Optase range of preservative free dry eye products, Aequus said in a July 6 press release.
- Under the agreement, Scope will supply the products while Aequus will be responsible for Canadian authorization, marketing, distribution, and sales activities.
- Aequus added that it will have first right of refusal on any new products Scope intends to commercialize in Canada.
- Aequus noted that it expects to launch select products in Scope's portfolio later this year.
For further details see:
Aequus gets Canadian distribution rights for Scope's 10 eye products